-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

Benzinga·06/09/2026 16:35:14
Listen to the news
BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.